AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: An analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonaL antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)
- 浏览1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



